HC Wainwright Estimates LifeMD's Q2 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Research analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for LifeMD in a report issued on Wednesday, May 7th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of $0.02 per share for the quarter, down from their prior forecast of $0.03. HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for LifeMD's current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD's Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.16 EPS and Q4 2026 earnings at $0.22 EPS.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.05. The company had revenue of $65.70 million during the quarter, compared to the consensus estimate of $62.47 million.

Several other brokerages have also recently commented on LFMD. B. Riley raised LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 price target on shares of LifeMD in a research report on Tuesday, March 11th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, LifeMD presently has an average rating of "Buy" and an average target price of $11.00.

LifeMD Stock Performance

Shares of NASDAQ:LFMD traded up $0.86 during trading on Monday, reaching $10.53. The company had a trading volume of 960,525 shares, compared to its average volume of 949,193. The firm's fifty day moving average is $6.21 and its 200 day moving average is $5.81. The firm has a market capitalization of $478.57 million, a PE ratio of -16.40 and a beta of 2.22. LifeMD has a twelve month low of $3.99 and a twelve month high of $10.62.

Insider Activity

In other LifeMD news, CEO Justin Schreiber sold 21,995 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $7.53, for a total transaction of $165,622.35. Following the sale, the chief executive officer now directly owns 2,553,726 shares of the company's stock, valued at $19,229,556.78. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Jessica Friedeman sold 30,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the sale, the chief marketing officer now directly owns 170,000 shares of the company's stock, valued at $962,200. This trade represents a 15.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 101,995 shares of company stock worth $724,422. Insiders own 15.97% of the company's stock.

Institutional Investors Weigh In On LifeMD

Several institutional investors and hedge funds have recently modified their holdings of LFMD. CWM LLC raised its holdings in LifeMD by 17.5% during the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after buying an additional 1,351 shares in the last quarter. Prudential Financial Inc. increased its holdings in shares of LifeMD by 19.3% during the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company's stock valued at $67,000 after acquiring an additional 2,200 shares during the last quarter. Rhumbline Advisers raised its stake in shares of LifeMD by 6.1% in the 4th quarter. Rhumbline Advisers now owns 48,689 shares of the company's stock valued at $241,000 after acquiring an additional 2,814 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in LifeMD by 26.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock worth $70,000 after purchasing an additional 2,895 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in LifeMD by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 822,217 shares of the company's stock worth $4,071,000 after purchasing an additional 2,984 shares during the period. Institutional investors and hedge funds own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.